AllianceBernstein
ADMS

AllianceBernstein’s Adamas Pharmaceuticals ADMS Stock Holding History

AllianceBernstein’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-42,700
Closed -$123K – 3287
2020
Q1 		$123K Hold
42,700
– – ﹤0.01% 2914
2019
Q4 		$162K Hold
42,700
– – ﹤0.01% 2963
2019
Q3 		$218K Sell
42,700
-7,000
-14% -$43.2K ﹤0.01% 2915
2019
Q2 		$308K Buy
49,700
+1,700
+4% +$9.78K ﹤0.01% 2819
2019
Q1 		$341K Sell
48,000
-1,177,839
-96% -$10.6M ﹤0.01% 2696
2018
Q4 		$10.5M Buy
1,225,839
+379,460
+45% +$4.93M 0.01% 972
2018
Q3 		$16.9M Buy
846,379
+129,763
+18% +$3.05M 0.01% 835
2018
Q2 		$18.5M Buy
716,616
+59,510
+9% +$1.65M 0.01% 800
2018
Q1 		$15.7M Sell
657,106
-631
-0.1% -$19.9K 0.01% 833
2017
Q4 		$22.3M Buy
657,737
+77,303
+13% +$2.16M 0.02% 743
2017
Q3 		$12.3M Sell
580,434
-137,183
-19% -$2.51M 0.01% 891
2017
Q2 		$12.6M Buy
717,617
+17,972
+3% +$297K 0.01% 876
2017
Q1 		$12.2M Sell
699,645
-35,749
-5% -$609K 0.01% 880
2016
Q4 		$12.4M Buy
735,394
+36,886
+5% +$570K 0.01% 865
2016
Q3 		$11.5M Buy
698,508
+46,841
+7% +$712K 0.01% 860
2016
Q2 		$9.87M Sell
651,667
-8,093
-1% -$133K 0.01% 880
2016
Q1 		$9.54M Buy
659,760
+651,160
+7,572% +$11M 0.01% 863
2015
Q4 		$244K Buy
+8,600
New +$145K ﹤0.01% 2684
2015
Q2 		– Sell
-3,700
Closed -$65K – 3348
2015
Q1 		$65K Buy
3,700
+3,300
+825% +$56.5K ﹤0.01% 3100
2014
Q4 		$7K Hold
400
– – ﹤0.01% 3342
2014
Q3 		$7K Sell
400
-400
-50% -$6.88K ﹤0.01% 3332
2014
Q2 		$15K Buy
+800
New +$14.3K ﹤0.01% 3270

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

AllianceBernstein's ADMS Position: Q2 2020 in Review

AllianceBernstein sold out of Adamas Pharmaceuticals (ADMS) in Q2 2020, closing a stake of 42,700 shares — an estimated $123K sold.

AllianceBernstein first reported a position in ADMS in Q2 2014 and held it in 22 quarters. The position peaked at $22.3M in Q4 2017. 61 funds tracked by Wall St. Rank hold ADMS as of Q2 2020.

  • AllianceBernstein reported no remaining Adamas Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • AllianceBernstein sold 42,700 Adamas Pharmaceuticals shares in Q2 2020, an estimated $123K.
  • AllianceBernstein first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 22 quarters.
  • AllianceBernstein's Adamas Pharmaceuticals position peaked at $22.3M in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2020.

Based on AllianceBernstein's 13F filing for Q2 2020, filed 13 Aug 2020.